Investigation of annexin A5 as a biomarker for Alzheimer's disease using neuronal cell culture and mouse model

Journal of Neuroscience Research

Volumn 88, Issue 12, 2010, Pages 2682-2692

  Yamaguchi, Mami ^a   Kokai, Yasuo ^a   Imai, Shin Ichi ^a   Utsumi, Kumiko ^b   Matsumoto, Kyoichi ^c   Honda, Hirohito ^d   Mizue, Yuka ^e   Momma, Masako ^f   Maeda, Tetsu ^g   Toyomasu, Shozo ^g   Ito, Yoichi M ^h   Kobayashi, Seijyu ^a   Hashimoto, Eri ^a   Saito, Toshikazu ^a   Sohma, Hitoshi ^a,f  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SUNAGAWA CITY MEDICAL CENTER   (Japan)

^c SRL INC   (Japan)

^d SANYO CHEMICAL INDUSTRIES LTD   (Japan)

^e Sapporo Immuno Diagnostic Laboratory   (Japan)

^f SAPPORO MEDICAL UNIVERSITY   (Japan)

^g Kushiro Kita Hospital   (Japan)

^h HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

A ; Alzheimer's disease; Annexin A5; Biomarker; Ca2+ stress

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; CALCIUM ION; LIPID; LIPOCORTIN 5; PHOSPHOLIPID BINDING PROTEIN; PROTEIN;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BRAIN CORTEX; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; INCUBATION TIME; INTESTINE; KIDNEY; LIVER; LUNG; MAJOR CLINICAL STUDY; MOUSE; MUTANT; NERVE CELL; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SUPERNATANT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANNEXIN A5; BIOLOGICAL MARKERS; CALCIUM SIGNALING; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; MALE; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; NEURONS; ORGAN SPECIFICITY;

EID: 77955507349     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22427     Document Type: Article

References (43)

1. Ambrose MP, Hunninghake GW. 1990. Corticosteroids increase lipocortin I in alveolar epithelial cells. Am J Respir Cell Mol Biol 3:349-353.
2. Arai H, Emson PC, Mountjoy CQ, Carassco LH, Heizmann CW. 1987. Loss of parvalbumin-immunoreactive neurones from cortex in Alzheimer-type dementia. Brain Res 418:164-169. (Pubitemid 17155596)
3. Bedrood S, Jayasinghe S, Sieburth D, Chen M, Erbel S, Butler PC, Langen R, Ritzel RA. 2009. Annexin A5 directly interacts with amyloidogenic proteins and reduces their toxicity. Biochemistry 48:10568-10576.
4. Caserta MT, Caccioppo D, Lapin GD, Ragin A, Groothuis DR. 1998. Blood-brain barrier integrity in Alzheimer's disease patients and elderly control subjects. J Neuropsychiatry Clin Neurosci 10:78-84.
5. Christmas P, Callaway J, Fallon J, Jones J, Haigler HT. 1991. Selective secretion of annexin 1, a protein without a signal sequence, by the human prostate gland. J Biol Chem 266:2499-2507.
6. Dickson DW. 2004. Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect? J Clin Invest 114:23-27.
7. Eberhard DA, Brown MD, VandenBerg SR. 1994. Alteration of annexin expression in pathological neuronal glial reactions. Immunohistochemical localization of annexins I, II (p36 and p11 subunits), IV, and VI in the human hippocampus. Am J Pathol 145:640-649.
8. Gerke V, Moss SE. 2002. Annexins: from structure to function. Physiol Rev 82:331-371.
9. 2+ signaling to membrane dynamics. Nat Rev Mol Cell Biol 6:449-461.
10. Griffin WST, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. 1989. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86:7611-7615. (Pubitemid 19254506)
11. Hasegawa K. 1983. The clinical assessment of dementia in the aged: a dementia screening scale for grading the cognitive state of patients for clinician. In: Bergener M, editor. Aging in the eighties and beyond. New York: Springer. p207-218.
12. 2+- dependent apoptosis. Proc Natl Acad Sci U S A 99:8054-8059.
13. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Youkin S, Yang F, Cole G. 1996. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
14. Iacopino AM, Christakos S. 1990. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci U S A 87:4078-4082. (Pubitemid 20217984)
15. Ijuin M, Homma A, Miura M, Kitamura S, Kawai Y, Imai Y, Gondo Y. 2008. Validation of the 7-minute screen for the detection of early-stage Alzheimer's disease. Dement Geriatr Cogn Disord 25:248-255.
16. Inaguma Y, Shinohara H, Inagaki T, Kato K. 1992. Immunoreactive parvalbumin concentrations in parahippocampal gyrus decrease in patients with Alzheimer's disease. J Neurol Sci 110:57-61.
17. Johnson MD, Kamso-Pratt JM, Whetsll JWO, Pepinsky RB. 1989. Lipocortin-1 immunoreactivity in the normal human central nervous system and lesions with astrocytosis. Am J Clin Pathol 92:424-429.
18. 1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 44:14-26.
19. Kaneko N, Matsuda R, Hosoda S, Kajita T, Ohta Y. 1996. Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction. Clin Chim Acta 251:65-80. (Pubitemid 26227627)
20. Kato K, Kurobe N, Suzuki F, Morishita R, Asano T, Sato T, et al. 1991. Concentrations of several proteins characteristic of nervous tissue in cerebral cortex of patients with Alzheimer's disease. J Mol Neurosci 3:95-99.
21. Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
22. LaFerla FM. 2002. Calcium dyshomeostasis and intracellular signaling in Alzheimer's disease. Nat Rev Neurosci 3:862-872.
23. Lampl Y, Lorberboym M, Blankenberg FG, Sadeh M, Gilad R. 2006. Annexin V SPECT imaging of phosphatidylserine expression in patients with dementia. Neurology 66:1253-1254.
24. Lee G, Pollard HB, Arispe N. 2002. Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-β-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides 23:1249-1263. (Pubitemid 34786704)
25. Masliah E, Cole GM, Hansen LA, Mallory M, Albright T, Terry RD, et al. 1991. Protein kinase C alteration is an early biochemical marker in Alzheimer's disease. J Neurosci 11:2759-2767.
26. Masuda J, Takayama E, Satoh A, Ida M, Shinohara T, Kojima-Aikawa K, et al. 2004. Levels of annexin IV and V in the plasma of pregnant and postpartum women. Thromb Haemost 91:1129-1136.
27. Mattson MP. 2004. Pathways towards and away from Alzheimer's disease. Nature 430:631-639.
28. McKee AC, Kosik KS, Kennedy MB, Kowall NW. 1990. Hippocampal neurons predisposed to neurofibrillary tangle formation are enriched in type II calcium/calmodulin-dependent protein kinase. J Neuropathol Exp Neurol 49:49-63.
29. McLachlan DR, Wong L, Bergeron C, Baimbridge KG. 1987. Calmodulin and calbindin D28K in Alzheimer disease. Alzheimer Dis Assoc Disord 1:171-179.
30. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev MA, Hajjar KA. 1999. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 340:994-1004.
31. Ohkawa H, Sohma H, Sakai R, Kuroki Y, Hashimoto E, Murakami S, et al. 2002. Ethanol-induced augmentation of annexin IV in cultured cells and the enhancement of cytotoxicity by overexpression of annexin IV by ethanol. Biochim Biophys Acta 1588:217-225.
32. Pepinsky RB, Sinclair LK, Browning JL, Mattaliano RJ, Smart JE, Chow PE, et al. 1986. Purification and partial sequence analysis of a 37-kDa protein that inhibits phospholipase A2 activityfrom rat peritoneal exudates. J Biol Chem 261:4239-4246.
33. Pfäffle M, Ruggiero F, Hofmann H, Fernández MP, Selmin O, Yamada Y, et al. 1988. Biosynthesis, secretion and extracellular localization of anchorin CII, a collagen-binding protein of the calpactin family. EMBO J 7:2335-2342.
34. Rand JH, Wu X-X, Andree HAM, Ross JBA, Rusinova E, Gascon-Lema MG, et al. 1998. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood 92:1652-1660.
35. Romisch J, Heimburger N. 1990. Purification and characterization of six annexins from human placenta. Biol Chem Hoppe Seyler 3711:383-388. (Pubitemid 20192423)
36. Saito K, Elce JS, Hamos JE, Nixon RA. 1993. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A 90:2628-2632.
37. Saitoh T, Masliah E, Jin LW, Cole GM, Wieloch T, Shapiro IP. 1991. Protein kinases and phosphorylation in neurologic disorders and cell death. Lab Invest 64.
38. Satoh T, Tabira T, Sano M, Nakayama H, Tateishi J. 1991. Parvalbumin-immunoreactive neurons in the human central nervous system are decreased in Alzheimer's disease. Acta Neuropathol 81:388-395.
39. Sohma H, Creutz CE, Gasa S, Ohkawa H, Akino T, Kuroki Y. 2001a. Differential lipid specificities of the repeated domains of annexin IV. Biochim Biophys Acta 1546:205-215.
40. Sohma H, Ohkawa H, Akino T, Kuroki Y. 2001b. Binding of annexins to lung lamellar bodies and the PMA-stimulated secretion of annexin V from alveolar type II cells. J Biochem 130:449-455. (Pubitemid 32845700)
41. Sohma H, Ohkawa H, Hashimoto E, Toki S, Ozawa H, Kuroki Y, et al. 2001c. Alteration of annexin IV expression in alcoholics. Alcohol Clin Exp Res 25:55S-58S.
42. Sutherland MK, Wong L, Somerville MJ, Yoong LK, Bergeron C, Parmentier M, et al. 1993. Reduction of calbindin-28k mRNA levels in Alzheimer as compared with Huntington hippocampus. Brain Res Mol Brain Res 18:32-42.
43. Wu X-X, Arslan AA, Wein R, Reutelingsperger CP, Lockwood CJ, Kuczynski E, et al. 2006. Analysis of circulating annexin A5 parameters during pregnancy: absence of differences between women with recurrent spontaneous pregnancy losses and controls. Am J Obstet Gynecol 195:971-977.